Dr. Hui Wang: A Simple and Rapid Multi-Parameter Flow Cytometry Approach for the Diagnosis and Screening of Malignant Tumors and Related Diseases

Dr. Hui Wang: A Simple and Rapid Multi-Parameter Flow Cytometry Approach for the Diagnosis and Screening of Malignant Tumors and Related Diseases

2023.10.12
From June 8 to 12, 2023, the 28th European Hematology Association (EHA) Congress will be held in Frankfurt, Germany, bringing together experts and scholars from around the world to present exciting advances in research. In the field of hematology testing, multi-parameter flow cytometry (MFC) is an important clinical diagnostic method, and the development of fast, simple, and efficient protocols is essential for this technology. A real-world study (P588) conducted by Dr.  Hui Wang's team from Hebei Yanda Ludaopei Hospital and Beijing Ludaopei Hospital has been selected for presentation at EHA.
Dr. Daobin Zhou’s Team: Zanubrutinib combined with R-CHOP regimen demonstrates efficacy and safety in primary treatment of Intravascular Large B-Cell Lymphoma

Dr. Daobin Zhou’s Team: Zanubrutinib combined with R-CHOP regimen demonstrates efficacy and safety in primary treatment of Intravascular Large B-Cell Lymphoma

2023.10.12
Intravascular Large B-Cell Lymphoma (IVLBCL) is a subtype of large B-cell lymphoma, characterized by large tumor B-cells aggregating inside blood vessels. This disease is extremely rare and highly malignant, often involving the central nervous system, lungs, and skin. Its prognosis is poor and clinical treatment challenging. At the recently concluded 28th European Hematology Association (EHA) Annual Meeting, a study (Abstract Number: P1185) from Dr. Daobin Zhou's team at Peking Union Medical College Hospital was selected. This study evaluated the efficacy and safety of the Zanubrutinib combined with R-CHOP regimen in treating initial IVLBCL, attracting widespread attention. To further understand this study, the Oncolgy Fronter invited Dr. Zhou for a detailed interpretation and analysis, summarized as follows:
Dr. Ryan Jacobs: Bispecific Antibodies Bring New Progress in Follicular Lymphoma Treatment, New CD79b ADC Drugs Show Significant Value in DLBCL Treatment!

Dr. Ryan Jacobs: Bispecific Antibodies Bring New Progress in Follicular Lymphoma Treatment, New CD79b ADC Drugs Show Significant Value in DLBCL Treatment!

2023.10.12
The annual European Hematology Association (EHA) conference was recently held in Frankfurt, Germany, in a hybrid online and offline format. As the largest international conference in the European hematology field, the EHA meeting covered a wide range of scientific topics, clinical and basic research, including benign and malignant hematology, discussing the latest developments in the field of hematology.
Dr. Niels Van de Donk Interprets the Latest Research Progress on CAR-T Treatment for RRMM

Dr. Niels Van de Donk Interprets the Latest Research Progress on CAR-T Treatment for RRMM

2023.10.12
From June 8th to 11th, 2023, the 28th European Hematology Association (EHA) was held in Frankfurt, Germany, both online and offline. The conference was hosted by the European Hematology Association. As the largest international conference in the European hematology field, it attracts over 10,000 professionals from more than 100 countries each year to share and discuss innovative concepts and the latest scientific and clinical research results in hematology.
Dr. Amir Fathi Interprets the Latest Developments in Targeted Therapy for Acute Myeloid Leukemia (AML)

Dr. Amir Fathi Interprets the Latest Developments in Targeted Therapy for Acute Myeloid Leukemia (AML)

2023.10.12
The annual European Hematology Association (EHA) meeting was successfully held both online and offline from June 8th to 11th, 2023, local time, in Frankfurt, Germany. As the largest international conference in the European hematology field, it attracts over ten thousand professionals from more than 100 countries every year, sharing and discussing innovative ideas and the latest scientific and clinical research results in hematology.